Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BioIBS
- Development stage
- Unknown
- Lead developer
- Takgene
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
BioIBS is a probiotic dietary supplement developed and marketed by Takgene Pharma specifically formulated to manage and alleviate the symptoms of irritable bowel syndrome (IBS). It contains a high-dose blend of three beneficial probiotic bacterial strains: *Lactobacillus acidophilus*, *Lactobacillus casei*, and *Lactobacillus rhamnosus*. BioIBS works by restoring the balance of the gut microbiota, strengthening the intestinal epithelial barrier, and modulating local immune and inflammatory responses. It helps reduce abdominal pain, bloating, flatulence, and visceral hypersensitivity, while regulating bowel movements in patients with diarrhea-predominant (IBS-D), constipation-predominant (IBS-C), or mixed (IBS-M) subtypes of irritable bowel syndrome.
- Brand names
- BioIBS
- Other names
- BioIBS Probioticبایو آی بی اس
Beyond the preview
Go deeper on BioIBS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioIBS.